IRF2 and cancer: While we didn’t resolve which of the IRF2-regulated MHC I components became functionally limiting in these cancer cells, we had previously shown that in IRF2 null cells, TAP and ERAP1 functions (peptide transport into the ER and subsequent peptide trimming) are inhibited, as is overall antigen presentation [6].